Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Ardelyx (ARDX – Research Report) on May 2 and set a price target of $10.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Roanna Ruiz’s rating is based on Ardelyx’s solid commercial execution despite facing challenges in the first quarter, such as the seasonal contraction in the IBS-C market and the loss of Medicare Part D coverage for Xphozah. The company has maintained its guidance for Ibsrela, showing strong momentum with expected revenues between $240-250M for 2025. Additionally, management has effectively navigated the Medicare Part D transition for Xphozah, with positive indicators in the non-Medicare segments.
Furthermore, Ardelyx’s management has reaffirmed their long-term peak sales targets, citing growth drivers such as increased clinical conviction among prescribers and an upsized sales force. The company also maintains a robust cash position, providing flexibility for continued commercial investment and business development opportunities. These factors, despite a slight reduction in the price target, support the Buy rating given by Roanna Ruiz.
In another report released on May 2, BTIG also reiterated a Buy rating on the stock with a $14.00 price target.